Increasing prevalence of chronic diseases is expected to drive the growth of global vulvovaginal candidiasis treatment in the forecast period, 2024-2028.
According to TechSci Research report, “Vulvovaginal Candidiasis Treatment Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F”, the global dental contouring market is anticipated to grow at an impressive rate in the forecast period, 2024-2028. This can be ascribed to the increasing prevalence of diabetes cases and increasing unrestrained usage of antibiotics leading to high prevalence of yeast infection among individuals across the globe. Additionally, increasing demand for better treatment and the rising burden of different chronic diseases like neurological disorder, and cancer, especially in the developed countries in the North America and Europe, are expected to create lucrative opportunities for market growth in the coming years. Besides, increasing research and development activities in healthcare industry is further expected to support the market growth. Similarly, growing approval of newly developed antifungal drugs and increasing the number of market players are expected to boost market growth during the forecast period. Also, growing awareness about new drugs for the treatment of fungal diseases and growing demand for advanced therapeutic options will drive the market growth over the years.
However, increasing resistance for antifungal drugs among the population is slowing down the growth of global vulvovaginal candidiasis treatment market in the forecast period. Similarly, high risks and complications associated with drugs such as the incidence of miscarriage due to fluconazole and treatments may hamper the vulvovaginal candidiasis treatment market growth during the forecast period. Also, the lack of awareness about maintaining good hygiene among the female population, in emerging countries, can further restrict the growth of the global vulvovaginal candidiasis treatment market.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on “Global Vulvovaginal Candidiasis Treatment Market“
The global vulvovaginal candidiasis treatment market can be segmented by drug class, by route of administration, by distribution channel and by region.
Based on drug class, the global vulvovaginal candidiasis treatment market can be segmented into Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others. The clotrimazole segment dominated the market in 2022 and is expected to continue maintaining its dominance throughout the forecast period. This can be ascribed to high efficiency and increasing usage of clotrimazole drug for the treatment of acute vulvovaginal candidiasis disease.
Based on route of administration, the market can be segmented into Oral, Intravenous, Topical. The oral segment is expected to dominate during the forecast period on account of the fact that most of the acute vulvovaginal candidiasis treatment drugs are taken orally and increasing the large patient pools in the hospitals. Similarly, the increasing demand for prescription products because of growing moderate to severe disease cases will further propel the market growth over the years.
Major companies operating in global vulvovaginal candidiasis treatment market are:
- Astellas Pharma Inc.
- Mycovia Pharmaceuticals, Inc.
- Basilea Pharmaceutica Ltd.
- Scynexis, Inc.
- Grupo Ferrer Internacional, S.A.
- Pfizer, Inc.
- Pacgen Life Science Corporation
- NovaDigm Therapeutics, Inc.
- Cidara Therapeutics, Inc.
- Amplyx Pharmaceuticals Inc.
For instance, on August 26, 2020, Mycovia Pharmaceuticals, Inc. published positive results for the Phase II clinical trials, which was conducted for testing the safety and efficacy of their oral drug candidate oteseconazole (VT-1161), an antifungal drug, for the treatment of vulvovaginal candidiasis.
For instance, on April 29, 2020, researchers at the University of Bristol, U.K. found that C12AHL, a chemical released from the bacterial species Pseudomonas aeruginosa, acts as the chemical signal for Candida species.
Customers can also request for 10% free customization on this report.
“North America is expected to dominate in the global vulvovaginal candidiasis treatment market due to the developed reimbursement procedures for the diagnosis and testing of vaginal fungal infection. Similarly, increasing the number of hospital-acquired infections is expected to propel the growth of the market over the years. Furthermore, the increasing prevalence of vaginal fungal infections among the population and major key players investing in the research and development sector for developing new drugs for the treatment is further contributing to the demand for vulvovaginal candidiasis treatment. Also, the presence of other tropical products the counter and prescription formulations will drive the market growth during the forecasted period. Besides, the availability of skilled professionals and early adoption of advanced treatments for the treatment of different vulvovaginal candidiasis infections in the region, are further expected to create lucrative opportunities for the market growth” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Vulvovaginal Candidiasis Treatment Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Drug Class (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others), By Route of Administration (Oral, Intravenous, Topical), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region and Competition”, has evaluated the future growth potential of global vulvovaginal candidiasis treatment market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global vulvovaginal candidiasis treatment market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com
